bluuebunny/crossref_metadata_2025_split huggingface dataset:
Gender distribution in surgical pathology journal publications and editorial boards
Authors: Nguyen Minh Anh , Yousef Samer , Gupta Ruta , McKenzie Catriona 
Published: May 2023

AimsTo investigate trends in representation of women among authors and editorial boards of surgical pathology journals over the last two decades.Secondary aims: to identify barriers and potential solutions.MethodsThe names and gender of first, middle, last authors and editorial board members were obtained from original articles from seven pathology journals from various geopolitical regions in 2002, 2011 and 2021. The proportion of women first, middle, last authors and editorial board members were compared over time.Results1097 publications and 8012 individual authors were extracted. In 2002, 2011 and 2021, respectively, the percentage of women first authors were 28.3% (257 of 907), 31.9% (566 of 1773) and 41.1% (1421 of 3457); women middle authorship rates were 30.0% (159 of 530), 32.8% (375 of 1145) and 40.9% (1067 of 2609) and women last authors were 18.0% (34 of 188), 26.0% (82 of 315) and 36.0% (152 of 422). Women representation on editorial boards has increased (11.3%, 15.8%, 26.5%), but of the chief editors, there was only one woman in 2021, while all were men in 2002 and 2011.ConclusionsTo our knowledge, this study is the first to document under-representation of women among authors and editorial boards of surgical pathology journals. While women representation has increased over time, predominance of men remains relative to workforce proportions. Our findings are comparable to those from other medical fields and prompt the need to investigate the underlying causes for this imbalance and implement strategies to promote diversity, equity and inclusion in academic surgical pathology.
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
Authors: Ranoa Diana Rose E , Sharma Preeti , Schane Claire P , Lewis Amber N , Valdez Edward , Marada Venkata V V R , Hager Marlies V , Montgomery Will , Wolf Steven P , Schreiber Karin , Schreiber Hans , Bailey Keith , Fan Timothy M , Hergenrother Paul J , Roy Edward J , Kranz David M 
Published: May 2023

BackgroundTreatment of some blood cancers with T cells that express a chimeric antigen receptor (CAR) against CD19 have shown remarkable results. In contrast, CAR-T cell efficacy against solid tumors has been difficult to achieve.MethodsTo examine the potential of CAR-T cell treatments against ovarian cancers, we used the mouse ovarian cancer cell line ID8 in an intraperitoneal model that exhibits disseminated solid tumors in female C57BL/6J mice. The CAR contained a single-chain Fv from antibody 237 which recognizes a Tn-glycopeptide-antigen expressed by ID8 due to aberrant O-linked glycosylation in the absence of the transferase-dependent chaperoneCosmc. The efficacy of four Tn-dependent CARs with varying affinity to Tn antigen, and each containing CD28/CD3ζ cytoplasmic domains, were compared in vitro and in vivo in this study.ResultsIn line with many observations about the impact of aberrant O-linked glycosylation, the ID8Cosmcknock-out (ID8Cosmc-KO) exhibited more rapid tumor progression compared with wild-type ID8. Despite the enhanced tumor growth in vivo, 237 CAR and a mutant with 30-fold higher affinity, but not CARs with lower affinity, controlled advanced ID8Cosmc-KO tumors. Tumor regression could be achieved with a single intravenous dose of the CARs, but intraperitoneal administration was even more effective. The CAR-T cells persisted over a period of months, allowing CAR-treated mice to delay tumor growth in a re-challenge setting. The most effective CARs exhibited the highest affinity for antigen. Antitumor effects observed in vivo were associated with increased numbers of T cells and macrophages, and higher levels of cleaved caspase-3, in the tumor microenvironment. Notably, the least therapeutically effective CAR mediated tonic signaling leading to antigen-independent cytokine expression and it had higher levels of the immunosuppressive cytokine interleukin10.ConclusionThe findings support the development of affinity-optimized CAR-T cells as a potential treatment for established ovarian cancer, with the most effective CARs mediating a distinct pattern of inflammatory cytokine release in vitro. Importantly, the most potent Tn-dependent CAR-T cells showed no evidence of toxicity in tumor-bearing mice in a syngeneic, immunocompetent system.
Interprofessional palliative and end-of-life education: short-term and long-term outcomes – mixed-methods analysis
Authors: Shaulov Adir , Finkelstein Adi , Vashdi Inon , DeKeyser Ganz Freda , Kienski Woloski-Wruble Anna , Rubinstein Estelle , Marcus Esther-Lee , Lesser Lior , Shaham Dorith 
Published: May 2023

ObjectiveInterprofessional care is integral to end-of-life (EOL) and palliative care (PC) and may be suited for EOL and PC education.We evaluate the impact of an interprofessional EOL care curriculum on participants, during the course, on completion and 4 years laterusing quantitative (questionnaires) and qualitative (open-ended questions and interviews) methods.The course included 14 fifth and sixth-year medical students, 9 social work students and 7 nursing students enrolled in master’s degree programmes. Seventeen participants completed questionnaires 4 years later and eight participated in interviews.On postcourse questionnaires, participants attributed high value to interprofessional education (IPE) (4.77/5±0.50 on a Likert scale). Four years later, participants reported that IPE impacted their professional (3.65/5±1.11) and personal lives (3.94/5±1.09) and found PC IPE important (4.88/5±0.33).Conventional content analysis showed that the course enabled discussion of death and dying and provided an opportunity for a personal-emotional journey. It offered an approach to EOL care and an opportunity to experience interprofessional teamwork at the EOL resulting in behavioural change.Interprofessional EOL education resulted in meaningful and lasting self-reported personal and professional behavioural outcomes.
Decoy state semi-quantum key distribution
Authors: Dong Shuang , Mi Shang , Hou Qingcheng , Huang Yutao , Wang Jindong , Yu Yafei , Wei Zhengjun , Zhang Zhiming , Fang Junbin 
Published: May 2023

AbstractSemi-quantum key distribution describes a system in which a fully quantum user and classical user perform key distribution. The main advantage of key distribution is its security. Owing to the bottlenecks of existing technology, highly attenuated lasers and threshold detectors are required for semi-quantum key distribution; however, these components make semi-quantum key distribution susceptible to eavesdroppers. Our previous study presented the first semi-quantum key distribution experiment and verified the feasibility of the mirror protocol in 2021. Herein, we first build a semi-quantum key distribution channel model and use Gottesman-Lo-Lütkenhaus-Preskill theory to evaluate its safety performance in the case of a quasi-single photon source. Moreover, we determine that an eavesdropper can steal all information through the photon-number-splitting attack without being detected. Therefore, we add decoy states to the semi-quantum key distribution to estimate the furthest transmission distance and secure bit rate under asymptotic conditions. Semi-quantum key distribution can still be achieved safely with highly attenuated lasers and threshold detectors in 150 km.
Noncommutative gauge and gravity theories and geometric Seiberg–Witten map
Authors: Aschieri Paolo , Castellani Leonardo 
Published: June 2023

AbstractWe give a pedagogical account of noncommutative gauge and gravity theories, where the exterior product between forms is deformed into a $$\star$$
⋆
-product via an abelian twist (e.g. the Groenewold–Moyal twist). The Seiberg–Witten map between commutative and noncommutative gauge theories is introduced. It allows to express the action of noncommutative Einstein gravity coupled to spinor fields in terms of the usual commutative action with commutative fields plus extra interaction terms dependent on the noncommutativity parameter.
Modelling pyroclastic density currents of the April 2021 La Soufrière, St Vincent eruption: from rapid invasion maps to field-constrained numerical simulations
Authors: Gueugneau Valentin , Charbonnier Sylvain , Miller Victoria L. , Cole Paul , Grandin Raphaël , Dualeh Edna W. 
Published: June 2023

Abstract
The April 2021 La Soufrière of St Vincent eruption generated several pyroclastic density currents (PDCs) during the 2 weeks of the crisis, from 9 to 22 April. To support the hazard assessment team during this eruption, numerical simulations were performed in real time and generated rapid scenario-based PDC invasion maps with the two-phase version of the code VolcFlow, which was able to simulate both the concentrated and dilute regime of PDCs. To generate the maps, only the source properties (shape and location) and the initial volume used to generate the PDCs were varied, all other input parameters were kept constant and estimated from previous simulations. New simulations were then performed based on the field-based deposit map to assess the code's ability to simulate such PDCs. Results show that the syn-crisis invasion maps satisfactorily mimic the observed valley-confined PDCs, while unconfined dilute PDCs were overestimated. The results also highlight that simulation results are greatly improved with additional field-based data, which help constrain the PDC sequence. Numerous lessons were learned, including (1) how to choose the most critical input parameters, (2) the importance of syn-eruptive radar imagery and (3) the potential of this two-phase model for rapid hazard assessment purposes.
Pangaea's breakup: the roles of mantle plumes, orogens and subduction retreat
Authors: Dang Zhuo , Zhang Nan , Li Zheng-Xiang , Yan Peilong 
Published: June 2023

Abstract
What drives the breakup of a supercontinent remains contentious. Previously proposed mechanisms include mantle plumes, subduction retreat and basal traction from mantle convection. Here we review the geological record of plumes, orogens and subduction zones during the breakup of Pangaea and investigate the potential roles played by these factors through 4D spherical geodynamic modelling. We found that mantle plumes provided the dominant force that drove the breakup of Pangaea, particularly in triggering the initial breakup. Young orogens as continental lithospheric weak zones generally guided the development of continental rifts, consistent with the geological record that rifting within Pangaea commonly developed along pre-existing orogens. However, the marginal drag force produced by subduction retreat, and basal traction associated with subduction-related mantle flow, likely also played a role in the breakup of Pangaea. In addition, the weakening effect of plume-induced melts can sometimes help to break the continental lithosphere away from orogens, as exemplified by the breakup between Antarctica and Australia. Furthermore, geodynamic modelling suggests that subduction is responsible for generating mantle plumes. A particular such example is the formation of the Kerguelen plume, triggered by subduction along the northern margin of Australia, which facilitated the breakup between East Antarctica and Australia.
Exact Solutions of an Extended Jimbo-Miwa Equation by Three Distinct Methods
Authors: He Yinghui 
Published: May 2023

In this article, we focus on exact traveling wave solutions to an extended Jimbo-Miwa equation, which is an extension of the Jimbo-Miwa equation. First, an improved

G

′

/
G

-expansion method, extended

G

′

/
G

-expansion method, and improved two variable (

φ

′

/
φ

,

1
/
φ

) expansion method are introduced. Second, with these introduced methods, many new exact traveling wave solutions of EJM equation are constructed, including hyperbolic function solutions, trigonometric function solutions, and rational function solutions which contain many different parameters. Finally, we depict the physical explanation of the extracted solutions with the free choice of the different parameters by plotting some 3D and 2D illustrations. To the best of our knowledge, the received results have not been reported in other studies on the new extended JM equations. We hope that our results can help enrich the study of this new equation.
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
Authors: Chandarlapaty Sarat , Dickler Maura N. , Perez Fidalgo Jose Alejandro , Villanueva-Vázquez Rafael , Giltnane Jennifer , Gates Mary , Chang Ching-Wei , Cheeti Sravanthi , Fredrickson Jill , Wang Xiaojing , Collier Ann , Moore Heather M. , Metcalfe Ciara , Lauchle Jennifer , Humke Eric W. , Bardia Aditya 
Published: June 2023

Abstract

Purpose:
GDC-0927 is a novel, potent, nonsteroidal, orally bioavailable, selective estrogen receptor (ER) degrader that induces tumor regression in ER+ breast cancer xenograft models.

Patients and Methods:
This phase I dose-escalation multicenter study enrolled postmenopausal women with ER+/HER2− metastatic breast cancer to determine the safety, pharmacokinetics, and recommended phase II dose of GDC-0927. Pharmacodynamics was assessed with [18F]-fluoroestradiol (FES) PET scans.

Results:
Forty-two patients received GDC-0927 once daily. The MTD was not reached. The most common adverse events (AE) regardless of causality were nausea, constipation, diarrhea, arthralgia, fatigue, hot flush, back pain, and vomiting. There were no deaths, grade 4/5 AEs, or treatment-related serious AEs. Two patients experienced grade 2 AEs of special interest of deep vein thrombosis and jugular vein thrombosis, both considered unrelated to GDC-0927. Following dosing, approximately 1.6-fold accumulation was observed, consistent with the observed half-life and dosing frequency. There were no complete or partial responses. Pharmacodynamics was supported by &gt;90% reduction in FES uptake and an approximately 40% reduction in ER expression, suggesting ER degradation is not the mechanistic driver of ER antagonism. Twelve patients (29%) achieved clinical benefit; 17 patients (41%) showed a confirmed best overall response of stable disease. Baseline levels of ER and progesterone receptor protein and mutant ESR1 circulating tumor DNA did not correlate with clinical benefit.

Conclusions:
GDC-0927 appeared to be well tolerated with pharmacokinetics supporting once-daily dosing. There was evidence of target engagement and preliminary evidence of antitumor activity in heavily pretreated patients with advanced/metastatic ER+/HER2− breast cancer with and without ESR1 mutations.
Additional Oncogenic Alterations inRAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Authors: Bikas Athanasios , Ahmadi Sara , Pappa Theodora , Marqusee Ellen , Wong Kristine , Nehs Matthew A. , Cho Nancy L. , Haase Jacob , Doherty Gerard M. , Sehgal Kartik , Barletta Justine A. , Alexander Erik K. , Landa Iñigo 
Published: June 2023

AbstractPurpose:RAS mutations occur across the spectrum of thyroid neoplasms, and more tools are needed for better prognostication. The objective of this study was to evaluate how additional genetic events affecting key genes modify prognosis in patients with RAS-mutant thyroid cancers, and specifically differentiated thyroid cancers (DTC).Experimental Design:We performed a clinical–genomic analysis of consecutive patients with DTC, poorly differentiated (PDTC), or anaplastic thyroid cancer (ATC) between January 2014 and December 2021, in whom a custom-targeted next-generation sequencing assay was performed. Patients harboring RAS mutations were included, and we compared their clinical features and outcomes based upon the presence of additional oncogenic alterations.Results:Seventy-eight patients were identified, with 22% (17/78) harboring a driver RAS mutation plus an additional oncogenic alteration. All six (100%) ATCs had an additional mutation. Compared with DTCs harboring a solitary RAS mutation, patients with DTC with RAS and additional mutation(s) were more likely to be classified as American Thyroid Association high-risk of recurrence (77% vs. 12%; P &lt; 0.001) and to have larger primary tumors (4.7 vs. 2.5 cm; P = 0.002) and advanced stage (III or IV) at presentation (67% vs. 3%; P &lt; 0.001). Importantly, over an average 65-month follow-up, DTC-specific-mortality was more than 10-fold higher (20% vs. 1.8%; P = 0.011) when additional mutations were identified.Conclusions:Identification of key additional mutations in patients with RAS-mutant thyroid cancers confers a more aggressive phenotype, increases mortality risk in DTC, and can explain the diversity of RAS-mutated thyroid neoplasia. These data support genomic profiling of DTCs to inform prognosis and clinical decision-making.
Abstract 86: The Status of Government-Funded Radiotherapy Centres in Nigeria
Authors: Chidebe Runcie C.W. , Aruah Chinedu S. , Orjiakor Tochukwu C. , Uba Fatima , Shagaya Uchechukwu N , Ugwanyi Charles , Umar Aisha A , Ige Taofeeq , Asogwa Obinna C. , Ahmadu Oiza T , Ali-Gombe Musa , Adewumi Alabi , Okwor Vitalis C. , Jimoh Mutiu A , Bello Basheer , Eriba Lucy O. , Ahmed Yusuf A. , Bisalla Awwal , Itanyi Ukamaka , Balogun Ramatallah A , Alabi Suleiman , Pistenmaa David , Norman Coleman C. , Manjit Dosanjh 
Published: June 2023

Abstract
Purpose: Access to radiotherapy (RT) is now one of the stark examples of global cancer inequities. Over 800,000 new cancer cases require potentially curative or palliative RT services in Africa, arguably less than 15% of these patients currently have access to this important service. For a population of over 200 million, Nigeria requires a minimum of 280 RT machines for the increasing number of cancer cases. Painfully the country has only 8 government-funded radiotherapy machines. This study aimed to evaluate the status of the eight (8) Government-funded RT centres in Nigeria regarding RT equipment, workforce and infrastructure to quantify their ability to deliver effective RT to their patients.
Methods: A survey addressing ten (10) critical areas was used to assess the eight (8) Government-funded RT centres in Nigeria.
Results: Unfortunately, 6 of the 8 centres (75%) surveyed have not treated patients with RT over the last 2 years because they do not have functioning teletherapy machines. Only 2 RT centres have the capability of treating patients using advanced RT techniques. There is no PET-CT scan in any of the Government-funded RTcentres. The workforce capacity and infrastructure across the 8 centres are limited. All of the centres lack residency training programmes for medical physicists and radiation therapy technologists (RTTs) resulting in very few well-trained staff.
Conclusion: As the Nigeria government plans for the new National Cancer Control Plan, there is an urgent need to scale up access to radiotherapy by upgrading the RT equipment, workforce and infrastructure to meet the current needs of Nigerian cancer patients. While the shortfall is apparent from a variety of radiotherapy-capacity data bases, this detailed analysis provides essential information for an implementation plan involving solutions from within Nigeria and with global partners.
Citation Format: Runcie C.W. Chidebe, Chinedu S. Aruah, Tochukwu C. Orjiakor, Fatima Uba, Uchechukwu N Shagaya, Charles Ugwanyi, Aisha A Umar, Taofeeq Ige, Obinna C. Asogwa, Oiza T Ahmadu, Musa Ali-Gombe, Alabi Adewumi, Vitalis C. Okwor, Mutiu A Jimoh, Basheer Bello, Lucy O. Eriba, Yusuf A. Ahmed, Awwal Bisalla, Ukamaka Itanyi, Ramatallah A Balogun, Suleiman Alabi, David Pistenmaa, Coleman C. Norman, Dosanjh Manjit. The Status of Government-Funded Radiotherapy Centres in Nigeria [abstract]. In: Proceedings of the 11th Annual Symposium on Global Cancer Research; Closing the Research-to-Implementation Gap; 2023 Apr 4-6. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(6_Suppl):Abstract nr 86.
Categorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework
Authors: Honing Judith , Fitzgerald Rebecca C. 
Published: June 2023

Abstract
Barrett's esophagus is a precancerous condition that can progress in a stepwise manner to dysplasia and eventually esophageal adenocarcinoma (EAC). Once diagnosed, patients with Barrett's esophagus are kept on surveillance to detect progression so that timely intervention can occur with endoscopic therapy. Several demographic and clinical risk factors are known to increase progression toward EAC, such as longer Barrett's segments, and these patients are kept on tighter surveillance. While p53 IHC has been advocated as an adjunct to histopathologic diagnosis, use of this biomarker is variable, and no other molecular factors are currently applied. Given the new evidence available, it is time to consider whether other risk factors or tools could be applied in clinical practice to decide on closer or attenuated surveillance. In this commentary, we summarize the most relevant risk factors for Barrett's esophagus progression, highlight the most promising novel risk stratification tools—including nonendoscopic triage and commercial biomarker panels, and propose a new framework suggesting how to incorporate risk stratification into clinical practice.
Examining the Barriers and Opportunities for Human Papillomavirus Vaccine Delivery in Cancer Care Settings: A Mixed-Methods Study
Authors: Garcia Melany A. , Schlecht Nicolas F. , Rokitka Denise A. , Attwood Kristopher M. , Rodriguez Elisa M. 
Published: June 2023

Abstract

Although pediatric, adolescent, and young adult (PAYA) cancer survivors are at increased risks for secondary cancers, their HPV vaccine uptake rates are poor. Therefore, we conducted a mixed-methods study to identify the barriers and opportunities for HPV vaccine delivery among PAYA cancer care providers. We distributed a semistructured questionnaire to a professional organization comprised of PAYA oncology and hematology healthcare providers between April and July 2022. Questionnaire measures included demographic and practice characteristics, HPV vaccine knowledge, willingness, barriers, opportunities, and roles for HPV vaccine delivery. Descriptive characteristics were generated for quantitative data, and content analysis was used to identify themes. A total of 49 providers responded to our survey. A majority were female (68%) and non-Hispanic white (74%). Approximately 76% were oncology or hematology physicians, and most worked in a cancer center or children's hospital (86%). Over half (63%) had been practicing for &gt;15 years, and a majority saw patients ages 11 to 17. Although less than half reported discussing HPV vaccination with their patients, 69% were willing to become involved in HPV vaccine delivery. The most frequently reported barriers identified in our content analysis were related to system-level factors. Furthermore, providers identified opportunities within cancer prevention education, transitions in care, and at the system-level. Although barriers to HPV vaccination persist in cancer care, most providers perceived there to be opportunities to become involved in HPV vaccine delivery. Identifying strategies for PAYA oncology and hematology healthcare providers to adopt a stronger role in HPV vaccination remains a significant opportunity for future implementation research.

Prevention Relevance:
This mixed-methods study is the first to investigate and assess barriers and opportunities for HPV vaccine delivery among PAYA cancer healthcare providers. Our findings can serve as an important framework for future implementation research targeted towards HPV vaccine delivery in cancer clinical settings.
See related Spotlight, p. 545